J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck…

biopharmadive.com1 mese fa

In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to…

fiercepharma.com1 mese fa

Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple…

fiercepharma.com3 g fa

It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug…

fiercepharma.com1 mese fa

Aiming to bolster ivonescimab’s case ahead of a key FDA decision, Summit Therapeutics has provided

fiercepharma.com4 g fa

Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority…

benzinga.com1 mese fa

Other newsrooms on this story